BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on designing and developing innovative small molecule medicines to address significant unmet medical needs in cancer treatment. The company applies a chemistry-based approach, combining a deep understanding of disease and protein dynamics with structure-based rational drug design expertise. This allows them to identify structural liabilities in existing therapies and design novel chemical scaffolds to overcome these limitations. BlossomHill's pipeline includes several therapeutic candidates. Their initial development efforts are concentrated on two clinical-stage programs: BH-30643 and BH-30236. BH-30643 is an investigational OMNI-EGFR™ inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), particularly focusing on the C797S resistance population after 3rd generation EGFR TKI treatment. BH-30236 is an investigational CDC-like kinase (CLK) inhibitor being developed for relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). Additionally, BlossomHill has a preclinical program, BH-501284, a pan-KRAS Switch II inhibitor targeting activated KRAS mutations. The company was founded by J. Jean Cui, Ph.D., who has a track record as a cancer drug designer and developer, including three FDA-approved targeted cancer therapies. BlossomHill Therapeutics is headquartered in San Diego, California. Sources: [1] https://bhtherapeutics.com/about/ [2] https://ir.bhtherapeutics.com/ [3] https://www.globenewswire.com/news-release/2026/08/07/3340894/0/en/BlossomHill-Therapeutics-Announces-Pricing-of-Upsized-150-Million-Initial-Public-Offering.html [4] https://www.sec.gov/Archives/edgar/data/1839970/000119312526306506/d98958ds1.htm [5] https://www.tradingview.com/symbols/NASDAQ-BLSM/